Logo for Insmed Incorporated

Insmed Investor Relations Material

Latest events

Logo for Insmed Incorporated

Q3 2024

Insmed
Logo for Insmed

Q3 2024

31 Oct, 2024
Logo for Insmed

Q2 2024

8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Insmed Incorporated

Access all reports
Insmed Incorporated is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for patients living with serious and rare diseases. The Company's marketed product ARIKAYCE, or L-Amikacin, is approved in the United States for the treatment of Mycobacterium avium complex lung disease as part of a combination anti-mycobacterial drug regimen for adult patients who are refractory to or intolerant of conventional treatments.